Dialysis chain NephroPlus raises Rs 850 crores in Series F round from Quadria Capital
Advertisement
Hyderabad: Quadria Capital, an Asia\s healthcare-focused private equity firms, has announced an investment of INR 850 Crores in NephroPlus, Asia’s dialysis network.
Through this transaction, Quadria will acquire a significant minority stake through a combination of a primary investment and the purchase of shares from existing shareholders. The transaction will support NephroPlus in serving the growing demand for high quality, affordable dialysis services across India and other markets in Asia.
Founded in 2010, NephroPlus is a dialysis provider operating in sizeable, high-growth markets across Asia. The company serves patients across dialysis centres in marquee hospitals and at standalone clinics, working with leading nephrologists. NephroPlus also delivers care through public- private partnerships in both urban and rural areas.
Demand for dialysis services in the company’s target markets is expected to grow at a rate of over 11% annually over the next five years. Specialized chains such as NephroPlus are expected to gain market share as hospitals increasingly outsource dialysis operations and as governments seek to make high- quality dialysis services more accessible.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.